CN102660503A - Method for separating and amplifying mesenchymal stem cells from umbilical cord - Google Patents
Method for separating and amplifying mesenchymal stem cells from umbilical cord Download PDFInfo
- Publication number
- CN102660503A CN102660503A CN2012101604052A CN201210160405A CN102660503A CN 102660503 A CN102660503 A CN 102660503A CN 2012101604052 A CN2012101604052 A CN 2012101604052A CN 201210160405 A CN201210160405 A CN 201210160405A CN 102660503 A CN102660503 A CN 102660503A
- Authority
- CN
- China
- Prior art keywords
- umbilical cord
- tissue
- cell
- plate
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a method for separating and amplifying mesenchymal stem cells from an umbilical cord. The method comprises the following steps of: disinfecting and cleaning an umbilical cord tissue; cutting the tissue into pieces, and paving in another cell culture plate to ensure that the tissue pieces are air-dried until the tissue is attached to the plate; culturing the umbilical cord tissue in a culture medium special for the mesenchymal stem cells, supplementing/replacing liquid and clearing all umbilical cord tissue pieces when the umbilical cord tissue is cultured for 11 to 13 days, and continuing to culture; completely replacing liquid every 1 to 3 days later on; separating wall attaching cells from the bottom of the plate by using digestive enzyme when the fusion rate of the wall attaching cells in the plate reaches about 50-70 percent; centrifuging and removing a supernatant, adding into the culture medium special for the mesenchymal stem cells, suspending the cells again, and inoculating in a T25 cell culture bottle for subculture and amplification culture; and replacing liquid once every 1 to 3 days later on until the fusion rate reaches 70-90 percent to obtain the mesenchymal stem cells. The method can be effectively used for separating and amplifying the mesenchymal stem cells.
Description
Technical field
The present invention relates to from the umbilical cord flesh tissue to separate the method with expanding stem cells, particularly the method for separation and amplification of mesenchymal stem cells from the umbilical cord flesh tissue.
Background technology
Discover contain in the marrow abundant mescenchymal stem cell (mesenchymal stem cell, MSC) because this type cell has characteristics such as multidirectional differentiation potential, immunoregulation and self-replacation, so receive people's attention gradually.Mescenchymal stem cell can be induced to differentiate into multiple histocytes such as fat, bone, cartilage, muscle, tendon, ligament, nerve, liver, cardiac muscle, endothelium.Still have multidirectional differentiation potential after continuous passage cultivation and the freezing preservation, very big clinical value is arranged treating aging and injuries of tissues and organs reparation.
But along with wearing out of age, the stem cell number in the marrow also significantly reduces, the also decline significantly of proliferation and differentiation ability; Transplant and to cause immunoreation for allosome; Extract the stem cell process to the damaging of patient and the other problems that when gathering, runs into, all directly influenced the clinical application of mesenchymal stem cells MSCs, make and seek that other alternative mescenchymal stem cells sources become an important problem beyond the marrow.
Recent research shows, also contains mescenchymal stem cell in the umbilical cord tissue and can successfully separate.This tissue-derived mescenchymal stem cell has not only kept the biological characteristics of mescenchymal stem cell, and the stem cell of separating is more original, and stronger proliferation and differentiation ability is arranged.The functionally active of its immunocyte is low, has lowered the risk that triggers immunoreation and cause graft versus host disease greatly.Occult virus and infection by microorganisms and propagation probability are lower.Gatherer process is simple, and puerpera and newborn infant are not had any harm and damage.Above reason is enough to make umbilical cord mesenchymal stem cells to become the desirable surrogate of mesenchymal stem cells MSCs.
Therefore, this area need from umbilical cord separate with amplification of mesenchymal stem cells simply, effective means, to satisfy clinical demand.
Summary of the invention
The objective of the invention is to solve the existing defective of obtaining the umbilical cord mesenchymal stem cells method, the simply method of separation and amplification of mesenchymal stem cells from external umbilical cord of a kind of practicality is provided.The present invention finds to use and a kind ofly organizes adherent method can be effectively to separate former generation mesenchyme from umbilical cord tissue to do thin and cultivate.The present invention is based on this discovery and be accomplished.
Therefore, first aspect present invention provides from the umbilical cord flesh tissue separates and the method for amplification of mesenchymal stem cells, and this method may further comprise the steps:
(1) sterilization and clean: with alcohol with the umbilical cord tissue surface sterilization; Umbilical cord is cut off from the centre, be tiled on the plate; Utilize the PBS cleansing tissue, to reduce structural red corpuscle;
(2) the adherent processing of umbilical cord tissue: tissue is cut into bulk, is tiled in another cell cultures plate again, the tissue block quantity in each plate maintains 5-20 piece (for example 10-15 piece); (for example 5-25 minute, for example 10-15 minute) is attached on the plate until tissue to make the air-dry 2-50 of tissue block minute;
(3) umbilical cord tissue is cultivated: slowly add the mescenchymal stem cell special culture media along the plate edge and get final product to organizing to flood; Put plate into CO
2Concentration is that 37 ℃ of incubators of 5% are cultivated, and is cultured to 3-7 days and plate is taken out from incubator when (for example 4-6 days, for example the 5th day), adds an amount of (tissue is flooded to get final product) mescenchymal stem cell special culture media; When 9-11 days (for example the 10th day), the substratum in the plate is shifted out, add an amount of (tissue is flooded to get final product) fresh mescenchymal stem cell special culture media, continue to cultivate; When 11-13 days (for example the 12nd day), remove all umbilical cord tissue pieces and continue and cultivate; After this (for example per 2 days) were once changed liquid entirely in every 1-3 days;
(4) passage: when the attached cell fusion rate in the plate reaches the 50-70% left and right sides, use digestive ferment (for example TrypLE Express, invitrogen product) to make attached cell break away from the plate bottom; Centrifugal, remove supernatant, add mescenchymal stem cell special culture media suspension cell again, be inoculated in the T25 Tissue Culture Flask and go down to posterity and carry out amplification cultivation; After this liquid was changed once in (for example per 2 days) in every 1-3 days, after fusion rate reaches 70-90%, promptly got umbilical cord mesenchymal stem cells, went down to posterity in case of necessity;
And optional following one or more steps:
(5) to step (4) gained umbilical cord mesenchymal stem cells, detect at least one item of following project: cytoactive, cell contamination, inherited disease, HLA-ABC/DR join type;
(6) umbilical cord mesenchymal stem cells after step (4) gained is gone down to posterity is frozen in liquid nitrogen, subsequent use.
According to the method for first aspect present invention, wherein said umbilical cord is the flesh tissue of umbilical cord.
According to the method for first aspect present invention, wherein said umbilical cord tissue is handled and in Biohazard Safety Equipment, is carried out.
According to the method for first aspect present invention, wherein said culture dish is the culture dish of diameter 5-20cm, preferably the culture dish of the about 10cm of diameter.
According to the method for first aspect present invention, wherein said PBS is the sodium salt and/or the sylvite preparation of phosphoric acid, and its pH is 5.0-8.0 (preferred pH is 5.5-7.6, and preferred pH is 6.0-7.0).In one embodiment, the concentration of phosphate radical is 0.01-0.5M among the said PBS, preferred 0.02-0.1M.In hereinafter test of the present invention, used PBS is a sodium phosphate salt, and wherein the concentration of phosphate radical is 0.025M, and pH is 6.5.Need to prove that the inventor finds that PBS concentration and pH value in above-mentioned scope are little for the influential effect of the inventive method.
According to the method for first aspect present invention, wherein in the step (2), the tissue that shreds is the about 0.2-2.5 cubic centimetre of size, for example big or small about 0.5-1.5 cubic centimetre, and for example big or small about 1 cubic centimetre cube is block.
According to the method for first aspect present invention, wherein in the step (2), the tissue size that shreds is at the 0.5-1.5 cubic centimetre, and preferred 0.5-1.0 cubic centimetre is very preferred in the time of particularly big or small about 1 cubic centimetre.Although the intended tissue fragment helps the realization of the inventive method for a short time; Yet the inventor finds in test under 0.2 cubic centimetre, 0.5 cubic centimetre, 1 cubic centimetre three kinds of states; They are to increasing the adherent effect of umbilical cord tissue, shorten the effect aspect basically identicals such as time that attached cell climbs out of from tissue, and volume greater than after 1.5 cubic centimetres to increasing the adherent effect of umbilical cord tissue, shortening attached cell and significant disadvantageous effect is arranged from the effects such as time that tissue climbs out of.
According to the method for first aspect present invention, wherein in the step (2), the air-dry time of tissue block is 2-50 minute, for example 5-25 minute, and for example 10-15 minute.The inventor finds in 10-15 minute air-dry time; Umbilical cord tissue is adherent, to shorten attached cell be best from the effect aspects such as time that tissue climbs out of to increasing, and is shorter than 5 minutes or air-dry time all has significant difference when being longer than 25 minutes than air-dry time.
According to the method for first aspect present invention, comprise FBS, L-Glutamine, Gentamicin and DMEM-F12 in the wherein said mescenchymal stem cell special culture media.In one embodiment, the FBS that contains 10-20% in the said mescenchymal stem cell special culture media.In one embodiment, contain 15% the FBS of having an appointment in the said mescenchymal stem cell special culture media.In one embodiment, the L-Glutamine that contains 0.5-2% in the said mescenchymal stem cell special culture media.In one embodiment, contain 1% the L-Glutamine (L-glutaminate) of having an appointment in the said mescenchymal stem cell special culture media.In one embodiment, the Gentamicin (qingfengmeisu qiong) that contains 0.02-0.1% in the said mescenchymal stem cell special culture media.In one embodiment, contain 0.05% the Gentamicin of having an appointment in the said mescenchymal stem cell special culture media.In one embodiment, the DMEM-F12 that contains 80-90% in the said mescenchymal stem cell special culture media.In one embodiment, contain 84% the DMEM-F12 of having an appointment in the said mescenchymal stem cell special culture media.In one embodiment, contain the Gentamicin of the L-Glutamine of the FBS of 15 weight parts of having an appointment, about 1 weight part, about 0.05 weight part and the DMEM-F12 of about 84 weight parts in the said mescenchymal stem cell special culture media.The inventor finds; The mescenchymal stem cell substratum of DMEM-F12 that contains Gentamicin and about 84 weight parts of the L-Glutamine of the FBS of 15 weight parts of having an appointment, about 1 weight part, about 0.05 weight part is preferred especially, than the arbitrary component content in making this substratum change prescription 10% or more adherent at the increase umbilical cord tissue, shorten and have significant advantage aspect the effects such as time that attached cell climbs out of from tissue.
According to the method for first aspect present invention, wherein in the step (3), the umbilical cord tissue piece was cultivated 11-13 days altogether in substratum, wherein to replenish and change a subculture, this incubation time and condition are preferred.
According to the method for first aspect present invention, in step (5), it is to utilize the trypan blue staining to count the number of frozen front and back viable cell that said cytoactive detects.
According to the method for first aspect present invention, in step (5), said cell contamination detects and utilizes small amounts of cells to cultivate, and detects cell and whether receives the pollution of fungi and bacterium.In one embodiment; Whether it is to utilize the etiology method that said cell contamination detects, detect cell and receive and be selected from following one or multinomial infection: hepatitis B two double, third liver, virus of AIDS, cytomegalovirus, Epstein-Barr virus and syphilis, HbsAg, HbsAb, HBcAb, HbeAg, HbeAb, HCVAb, HIV-1/2Ab, CMV-IgM and EBV-IgA, TRUST.
According to the method for first aspect present invention, in step (5), it is the method for utilizing molecular genetics that said inherited disease detects, and detects freeze-stored cell and whether has inherited disease.
According to the method for first aspect present invention, in step (5), it is to detect cell HLA-ABC/DR phenotype that said HLA-ABC/DR joins type.
According to the method for first aspect present invention, in step (6), said umbilical cord mesenchymal stem cells is frozen in liquid nitrogen through the programmed cooling process.
According to the method for first aspect present invention, in step (6), said umbilical cord mesenchymal stem cells is present in the cells frozen storing liquid.In one embodiment, this cells frozen storing liquid comprises DMEM-F12, DMSO 99.8MIN. and rHSA.In one embodiment, this cells frozen storing liquid comprises about 65 parts DMEM-F12, about 10 parts DMSO 99.8MIN., about 15 parts rHSA.In one embodiment, this cells frozen storing liquid comprises 50% low sugar DMEM nutrient solution, 40%FBS, 10% DMSO 99.8MIN..
According to the method for first aspect present invention, this method may further comprise the steps:
(1) sterilization and cleaning: in Biohazard Safety Equipment, with fresh umbilical cord tissue surface sterilization, umbilical cord is cut off from the centre, be tiled on the aseptic 10cm cell cultures plate, utilize the PBS cleansing tissue, to reduce to organize top red corpuscle as far as possible with alcohol;
(2) the adherent processing of umbilical cord tissue: tissue is transferred in another 10cm cell cultures plate, tissue is cut into big or small 1cm
3Square shape, be tiled in another 10cm cell cultures plate, the tissue block quantity in each plate maintains the 10-15 piece, makes be attached on the plate until tissue in the air-dry 10-15 of tissue block minute;
(3) umbilical cord tissue is cultivated: slowly add mescenchymal stem cell special culture media (15%FBS+1%L-Glutamine+0.05%Gentamicin+84%DMEM-F12) along the plate edge and get final product to organizing to flood; Plate is placed CO
2Concentration is that 37 ℃ of incubators of 5% are cultivated, and takes out plate from incubator when being cultured to the 5th day, adds 5ml mescenchymal stem cell special culture media; The tenth day the media transfer in the plate, add the fresh mescenchymal stem cell special culture media of 15ml; Remove all umbilical cord tissue pieces at the 12 day and continue to cultivate, once changed liquid in after this per two days entirely;
(4) passage: the attached cell fusion rate when the plate the inside reaches about 60%; Digestive ferment capable of using (TrypLE Express) breaks away from the plate bottom to attached cell; Remove supernatant after centrifugal; And add mescenchymal stem cell special culture media suspension cell again, be inoculated in the T25 Tissue Culture Flask and go down to posterity, and carry out amplification cultivation; After this changed liquid in per two days once after fusion rate reaches 80%, promptly get, go down to posterity again in case of necessity.
Further, can be directed against above step (4) gained umbilical cord mesenchymal stem cells, detect at least one item of following project: cytoactive, cell contamination, inherited disease, HLA-ABC/DR join type.
Further, the umbilical cord mesenchymal stem cells after can above step (4) gained being gone down to posterity is frozen in liquid nitrogen, subsequent use.
Further; Can be with the frozen and relevant fetus information of record in liquid nitrogen of the cell after going down to posterity; And the biological characteristics and the multidirectional differentiation potential that carry out cell are identified; And pair cell carries out molecular genetics diagnosis, preserves all related datas of cell, sets up the DB of umbilical cord stem cell and carries out related with freeze-stored cell.Therefore among the present invention in one aspect; The method of setting up umbilical cord stem cell DB is provided; It comprises that first aspect present invention is separated and the step of amplification umbilical cord mesenchymal stem cells; And following steps: the cell after will going down to posterity is the frozen and relevant fetus information of record in liquid nitrogen, and carry out the biological characteristics and the evaluation of multidirectional differentiation potential of cell, and pair cell carries out the molecular genetics diagnosis; Preserve all related datas of cell, set up the DB of umbilical cord stem cell and carry out related with freeze-stored cell.
In addition, in first aspect of the present invention, provide from the umbilical cord flesh tissue and to have separated and the method for amplification of mesenchymal stem cells.Therefore second aspect present invention provides a kind of umbilical cord mesenchymal stem cells.
According to the umbilical cord mesenchymal stem cells of second aspect present invention, it obtains according to the said method of the arbitrary embodiment of first aspect present invention.
According to the umbilical cord mesenchymal stem cells of second aspect present invention, its cell purity is greater than 90%, for example greater than 95%.In one embodiment, said umbilical cord mesenchymal stem cells is after going down to posterity more than 3 generations, and cell purity is greater than 90%, for example greater than 95%.
Be further described in the face of the present invention down.The document that the present invention quoted, and the document of being quoted in the document, their full content is incorporated this paper by reference into.
In the present invention; In arbitrary technical scheme of the arbitrary aspect of the present invention; Its arbitrary technical characterictic is equally applicable to arbitrary embodiment of arbitrary aspect of the present invention, as long as they can not cause contradiction, and this being useful in each other in case of necessity can be done suitable modification.
In the present invention, term " umbilical cord mesenchymal stem cells " is meant the mescenchymal stem cell that derives from umbilical cord.Therefore in the present invention, particularly relate in the linguistic context of the present invention, term " umbilical cord mesenchymal stem cells " can exchange with " umbilical cord stem cell ", " stem cell ", " mescenchymal stem cell " and use, and indicates only if having clearly in addition.
In the present invention, term " PBS damping fluid " perhaps " PBS " be meant phosphate buffered saline buffer.Generality prescription and compound method and their general aspects that those skilled in the art know the PBS that under situation of the present invention, uses be pH value or pH scope for example.
In the present invention, term " umbilical cord " is meant neonatal umbilical cord, is meant the umbilical cord within 4 hours postpartum especially.
Mescenchymal stem cell (mesenchymal stem cell; MSC) for example human mescenchymal stem cell is separated from marrow the earliest; Derive from mesoblastic one type of tissue stem cell with multidirectional differentiation potential and self ability; Has ability (Caplan AI.Mesenchymal stem cells.J Orthop Res.1991 in vivo with under the external specified conditions to multiple adult cytodifferentiation such as scleroblast, chondrocyte, adipocyte, endotheliocyte, neurocyte, myocyte, liver cells; 9:641-650.Pittenger MF; Mackay AM, Beck SC, et al.Multilineage potential of adult human mesenchymal stem cells.Science.1999; 284:143-147).Up-to-date research shows that mescenchymal stem cell has immunomodulatory and hematopoiesis support effect, and is easy to foreign gene importing expression.Therefore the seed cell of mescenchymal stem cell during still tissue-engineered bone, cartilage and cardiac muscle make up; Important carrier cell in the gene therapy; And, in HSCT and organ transplantation, be with a wide range of applications because mescenchymal stem cell promotes hematopoietic reconstitution and the anti-host response function of inhibition of transplant.Mescenchymal stem cell has the characteristic of external adherent growth, utilizes this specific character, people successfully from multiple tissues such as liver, kidney, pancreas, muscle, cartilage, skin, peripheral blood separation and Culture go out mescenchymal stem cell.
The mescenchymal stem cell of being reported at present is mainly derived from marrow, adopts density gradient centrifugation to obtain.Though separation method is easy, donor is got marrow need experience a relatively more painful operation, and has very high infection chance in the process of drawing materials and after drawing materials; Because the content of MSC is extremely rare among the human bone marrow, per 10
5～10
6Approximately have only 1 in the individual mononuclearcell, and along with the increase at age, the quantity of mescenchymal stem cell, propagation and differentiation capability descend significantly all in the marrow, make it in research with use in the especially clinical application and be restricted.Originate from the umbilical cord of embryonic development period extraembryonic mesoderm and form, contain a large amount of mesenchyme compositions by a matter, blood vessel and nurse cell.
Up-to-date research shows and contains abundant stem cell in the umbilical cord, and separation and Culture goes out these multipotential stem cells and will open up a brand-new and abundant source for experimental study and clinical application from umbilical cord.
Thereby existing separate stem cells is set up the method for stem cell bank many shortcomings are arranged still, for example purity is not enough and/or quantity is not high, and then demonstrates the expectation that these methods still can not satisfy people.The for example invention of CN 101270349A (one Chinese patent application numbers 200810061267.6, open day on September 24th, 2008) disclosed being entitled as " placenta mesenchyma stem cell separates and the amplification in vitro cultural method "; The invention of CN 101693884A (one Chinese patent application numbers 200910117522.9, open day on April 14th, 2010) disclosed being entitled as method of separating and extracting stem cells " a kind of from placenta, umbilical cord or fatty tissue "; CN 102146359A (one Chinese patent application numbers 201110005964.1, open day on August 10th, 2011) disclosed being entitled as " extracted the method for primary mesenchymal stem cells and serum-free amplification " from placenta invention.These methods are further improved remaining aspect the purity of extract and/or the recovery.
The invention discloses a kind of from umbilical cord the methods of a large amount of separating mesenchymal stem cells, and this method capable of using is preserved umbilical cord mesenchymal stem cells and is set up the umbilical cord stem cell bank.Contriver of the present invention is summing up on the basis of separation and Culture mescenchymal stem cell in the past, and in conjunction with the adherent culture method, success separates in umbilical cord and obtaining a large amount of mescenchymal stem cells.The mescenchymal stem cell purity that the inventive method obtains is high, quantity is many, has the biological characteristics identical with mesenchymal stem cells MSCs, can be to differentiation such as scleroblast, chondrocyte, adipocyte, endotheliocyte, neurocyte.Because stem cell is inmature than adult stem cell in the umbilical cord; Content is abundant; Be with a wide range of applications clinically; We use conventional cell cryopreservation method that mescenchymal stem cell is frozen as bleeding of the umbilicus, set up the umbilical cord stem cell bank, for further investigation and the clinical treatment of stem cell lay the foundation later on.
Because contain abundant hemopoietic stem cell in the bleeding of the umbilicus, people set up unbilical blood bank and store these important Biological resources of umbilical hemopoietic stem cell, for multiple disease in the blood system and disease of immune system provide a kind of treatment means.Same umbilical cord mesenchymal stem cells is as a kind of more importantly stem cell resource; We use conventional cell cryopreservation method it to be chilled in-196 degrees centigrade medium-term and long-term preservation of profound hypothermia liquid nitrogen; Set up the umbilical cord stem cell bank, for stem-cell therapy is in the future preserved seed.
According to the method for the invention, wherein the shape of umbilical cord tissue piece, size, quantity and air-dry time all are that the factor of adherent effect is organized in influence, thereby directly influence attached cell from time that tissue climbs out of.The present invention of experimental data proof can effectively increase the adherent effect of umbilical cord tissue, shortens attached cell from time that tissue climbs out of.According to the method for the invention, wherein the mescenchymal stem cell culture medium prescription can successfully and effectively carry out amplification in vitro to umbilical cord mesenchymal stem cells.According to the method for the invention, wherein changing liquid has shortened attached cell with the setting of organizing clean-up time and has reached the time of specifying fusion rate.
The present invention is simple to operate, and is convenient and practical, can obtain a large amount of mescenchymal stem cells, and the differentiation performance is good, has the ability to cytodifferentiation such as scleroblast, adipocyte, chondrocyte, endotheliocyte, neurocyte.Comparison with existing method: MSC mainly adopts modus operandi extraction donor marrow or perfusion method to separate umbilical cord at present, and adherent culture obtains.It is few that this method is got cell quantity, and donor is being got the possibility that infection is all arranged after marrow is got in the marrow neutralization.The present invention's success separates the higher mescenchymal stem cell of a large amount of purity of acquisition in umbilical cord, and uses this method to set up the umbilical cord stem cell bank and lay in this stem cell that has application prospect.This method is simple and easy to do, and because umbilical cord is the same with bleeding of the umbilicus, the cell composition is inmature, and wide material sources conveniently are easy to get, and therefore method of the present invention will have broad application prospect in the clinical application of stem cell.
Embodiment
Can further describe the present invention through following embodiment, yet scope of the present invention is not limited to following embodiment.One of skill in the art can understand, and under the prerequisite that does not deviate from the spirit and scope of the present invention, can carry out various variations and modification to the present invention.The present invention carries out generality and/or concrete description to the material and the TP that are used in the test.Though for realizing that employed many materials of the object of the invention and working method are well known in the art, the present invention still does detailed as far as possible description at this.
Embodiment 1, from umbilical cord, separate and the method for amplification of mesenchymal stem cells
(1) sterilization and cleaning: umbilical cord tissue is handled and should be carried out at Biohazard Safety Equipment., cut off umbilical cord from the centre fresh umbilical cord tissue surface sterilization with alcohol, be tiled on the aseptic 10cm cell cultures plate.Utilize the PBS cleansing tissue, reduce to organize top red corpuscle as far as possible.
(2) the adherent processing of umbilical cord tissue: tissue is transferred in another 10cm cell cultures plate, is cut into big or small 1cm to tissue
3Square shape, be tiled in another 10cm cell cultures plate, the tissue block quantity in each plate maintains the 10-15 piece.Let be attached on the plate in the air-dry 10-15 of tissue block minute until tissue.
(3) umbilical cord tissue is cultivated: slowly add mescenchymal stem cell special culture media (15%FBS+1%L-Glutamine+0.05%Gentamicin+84%DMEM-F12) along the plate edge and get final product to organizing to flood.Put plate into CO
2Concentration is that 37 ℃ of incubators of 5% are cultivated, and takes out plate from incubator when being cultured to the 5th day, adds 5ml mescenchymal stem cell special culture media.The tenth day the media transfer of plate the inside, add the fresh mescenchymal stem cell special culture media of 15ml.Removed all umbilical cord tissue pieces at the 12 day and continue and cultivate.Once changed liquid in per backward two days entirely.
(4) passage: the attached cell fusion rate when the plate the inside reaches about 60%; Digestive ferment capable of using (TrypLE Express) breaks away from the plate bottom to attached cell; Centrifugal back is shifted supernatant and is added mescenchymal stem cell special culture media suspension cell again, is inoculated in the T25 Tissue Culture Flask and goes down to posterity and carry out amplification cultivation.Changed liquid and once after fusion rate reaches 80%, go down to posterity again in per backward two days.
In the test of above step, umbilical cord tissue began to have attached cell to climb out of at the 8th day that cultivates, and was cultured to the 14th day cell confluency and reached 60%.After being passaged to the T25 culturing bottle, reach 90% the 17th day fusion rate.After 3 generations went down to posterity, cell purity was greater than 95%.
In the test of above step, comprise 15 weight part FBS, 1 weight part L-Glutamine, 0.05 weight part Gentamicin and 84 weight part DMEM-F12 in the mescenchymal stem cell special culture media.In four kinds of components of this substratum, during wherein any three kinds of fixed ratio, alternative ratio does not all reach 75% the 17th day fusion rate after departing from said ratio 10% when above, being passaged to the T25 culturing bottle.For example in the mescenchymal stem cell special culture media that uses, comprise 1 weight part L-Glutamine, 0.05 weight part Gentamicin and 84 weight part DMEM-F12; And when 12 weight part FBS, 13.5 weight part FBS, 16.5 weight part FBS or 18 weight part FBS; Under four kinds of situation; After being passaged to the T25 culturing bottle, the 17th day fusion rate all between 50-74%.
Embodiment 2, from umbilical cord, separate and the method for amplification of mesenchymal stem cells
The method of reference implementation example 1 is carried out.Umbilical cord tissue began to have attached cell to climb out of at the 7th day that cultivates, and was cultured to the 13rd day cell confluency and reached 60%.After being passaged to the T25 culturing bottle, reach 90% the 19th day fusion rate.After 3 generations went down to posterity, cell purity was greater than 95%.
Embodiment 3, from umbilical cord, separate and the method for amplification of mesenchymal stem cells
The method of reference implementation example 1 is carried out.Umbilical cord tissue began to have attached cell to climb out of at the 8th day that cultivates, and was cultured to the 15th day cell confluency and reached 60%.After being passaged to the T25 culturing bottle, reach 90% the 18th day fusion rate.After 3 generations went down to posterity, cell purity was greater than 90%.
Embodiment 4, from umbilical cord, separate and the method for amplification of mesenchymal stem cells
The method of reference implementation example 1 is carried out.Umbilical cord tissue began to have attached cell to climb out of at the 7th day that cultivates, and was cultured to the 14th day cell confluency and reached 60%.After being passaged to the T25 culturing bottle, reach 90% the 17th day fusion rate.
Embodiment 5, from umbilical cord, separate and the method for amplification of mesenchymal stem cells
The method of reference implementation example 1 is carried out.Umbilical cord tissue began to have attached cell to climb out of at the 7th day that cultivates, and was cultured to the 13rd day cell confluency and reached 60%.After being passaged to the T25 culturing bottle, reach 90% the 20th day fusion rate.
The cultivation and frozen of going down to posterity of embodiment 6, umbilical cord MSC
The cell of each acquisition of embodiment 1-5 is digested, get 1 * 10 after the digestion
6Cell joins in the 1ml cells frozen storing liquid (containing 65 parts of DMEM-F12+10 part DMSO 99.8MIN.s+15 parts of rHSAs), and it is frozen to enter into liquid nitrogen container at last through programmed cooling.
The biological characteristics of embodiment 7, umbilical cord MSC is identified
1, cell growth and morphology characteristics thereof
Through the separation and Culture of embodiment 1 and embodiment 6, the cultivation of umbilical cord mononuclearcell can obviously be seen the fusiformis attached cell at microscopically after 72 hours, can form the turbine-like cell clone about 10 days, can form the adherent layer of about 80% fusions after the had digestive transfer culture.In the culturing process, find the relative homogeneous of this cellular form, rate of propagation is fast, and adherent speed is fast, is prone to be passaged to 5-15 generation by trysinization, and its form and growth characteristic also do not have obvious change.
2, flow cytometry identification of M SC surface marker
Get respectively the 3rd, 6,9,12,15 generation cell, the Flow cytometry cell surface marker dynamic observes the variation of cell surface marker in the culturing process.The digestion collecting cell gets 8 * 10 behind the counting
6Individual cell, packing 16 pipes; PBS washes once, the centrifugal 10min of 1500rpm; Abandon supernatant, residual 100～200 μ l, piping and druming mixing cell; Add CD45, CD105, HLA-ABC, HLA-DR, each 10 μ l of UEA-1 antibody of CD14, CD29, CD31, CD34, CD44, CD54, CD73, CD80, CD86, CD166 antibody and the FITC mark of PE mark, and establish a pipe and be blank; Under 4 ℃, lucifuge reaction 30min; PBS washes once, the centrifugal 10min of 1500rpm; Directly the cell of mark is abandoned supernatant, adds 200 μ l PBS piping and druming mixing cell, and 1% Paraformaldehyde 96 of 200 μ l is fixed, put 4 ℃ to be measured, the upflowing cell instrument detects in 3 days.
Flow cytometer detects the surface marker of cell, dynamic observes the cell in the 3rd, 6,9,12,15 generations, does not have obviously to change.Not expressing the hematopoietic cell surface marker is CD14, CD31, CD34 (HSPC and endotheliocyte are positive), CD45 (white corpuscle is positive), CD54 (ICAM-1), CD80 (B7-1), CD86 (B7-2), the lasting feminine gender of HLA-DR (MHC-II quasi-molecule); CD29 and CD44 (acceptor of scleroproein and transparency grease hydrochlorate, stroma cell is expressed), CD73 (being SH-3,4), CD105 (being SH-2), CD166 (mesenchymal cell expression), HLA-ABC (MHC-I quasi-molecule) and UEA-1 (surface marker of endotheliocyte) are continuously the positive.After going down to posterity more than 3 generations, the cellular constituent homogeneous, purity is more than 95%.
3, the cell cycle of Flow cytometry umbilical cord MSC
Cell grows to about 80% when merging, digestion collecting cell about 1 * 10
6Individual, PBS washes once, and the ethanol of adding 70% is fixed, and 4 ℃ to be measured.During detection, the centrifugal ethanol that goes is washed once with PBS more earlier, adds RNase I 500u, 37 ℃ of reaction 30min, and PBS washes once, adds propidium iodide (PI, final concentration 50 μ g/ml) 1ml, room temperature lucifuge reaction 20min, last machine testing cell DNA content.
Through measure the 3rd generation and the 6th generation cell dna content, cell cycle analysis, G
0/ G
1Phase, S phase and G
2M phase proportion is respectively 96.35%, 96.66%, 1.11%, 0.09% and 2.54%, 3.25%.The result shows that the cell of vitro culture has typical stem cells hyperplasia characteristics, promptly has only few cell to be in the active propagation phase (1.11%, 0.09%), and most cell is in quiescent stage (96.35%, 96.66%).
4, the drafting of umbilical cord MSC growth curve and the mensuration of logarithmic phase doubling time
The cell in vegetative period of taking the logarithm, the digestion counting is processed cell suspension (every hole inoculation 0.5ml in 2 * 104/ml), 24 orifice plates, 37 ℃, 5%CO with the LG-DMEM substratum of 10%FBS
2, cultivate under the saturated humidity.Get 3 multiple holes every day, trypan blue dyeing back living cell counting number, calculating mean value was observed 7 days continuously.With the incubation time is transverse axis, and cell count is the longitudinal axis, draws cell growth curve.Calculate cell in the doubling time of logarithmic phase with the Patterson formula, i.e. Td=Tlg2/Lg (Nt/No), Td: the doubling time (h), T: cell increases to Nt used time (h), N: cell count by No.
Cytometric result draws cell growth curve through every day, calculates the doubling time.Can find out that by cell growth curve cell was in exponential phase of growth at 2-4 days.According to formula calculate the 5th generation cell doubling time of exponential phase of growth in 18-30 hour scope.
5, the evaluation of the multidirectional differentiation potential of umbilical cord MSC
(1) osteogenic induction
Above MSC of 3 generations is by 1 * 10
5Six orifice plates are inoculated in/hole, are put in 37 ℃, 5%CO
2, under the saturated humidity, cultivate 24h in the MSC substratum after, use instead and contain 10% through the DMEM-HG of screening FBS and add DEXAMETHASONE BP98 0.1 μ M, ascorbyl phosphate 50 μ M, β-phospho-glycerol 10mM, be put in 37 ℃, 5%CO
2, under saturated humidity, cultivate, amount was changed liquid in per 3 days half, coinduction 2-4 week.Alkaline phosphatase staining identifies that scleroblast forms, and Von Kossa dyeing identifies that the bone tubercle forms.
Containing 10% DMEM-HG through screening FBS; Adding DEXAMETHASONE BP98 0.1 μ M, ascorbyl phosphate 50 μ M, β-phospho-glycerol 10mM cultivated for 1 week; Cellular form takes place significantly to change, and becomes polygon by fusiform inoblast appearance, is similar to neuronal cell appearance; It is outstanding that the long filament shape appears in the cell periphery, and can extend towards periphery.Continue to cultivate 2 weeks above after, calcified plaque appears in the cell matrix, mineralizer engenders, and begins to form the little junction structure of multilayer, after cultivating for 4 weeks, visible obviously calcification tubercle.The alkaline phosphatase staining of 2 whens week is strong positive reaction, reaches more than 95%, and in addition the inductive control group is then most of not negative, only is shown as the weak positive less than 5%, shows that cell transforms to scleroblast.Von Kossa dyeing can be dyed black with sedimentary calcium in the bone tubercle, induces the visible a large amount of black bone tubercle of group, tangible three-dimensional arrangement is arranged, and control group does not all have positive reaction at any time.
(2) become fat to induce
Above MSC of 3 generations is by 1 * 10
5/ hole is inoculated in six orifice plates, is put in 37 ℃, 5%CO
2, under the saturated humidity, in the MSC substratum, cultivate 24h after, use instead and contain 10% high sugared DMEM, and add DEXAMETHASONE BP98 1 μ M, INDOMETHACIN BP99 60 μ M, IBMX 0.5mM, Regular Insulin 5 μ g/ml through screening FBS, be put in 37 ℃, 5%CO
2, cultivate under the saturated humidity, amount was changed liquid in per 3 days half, and in 2 weeks of coinduction, oil red dyeing identifies that fat drips formation.
Containing 10% DMEM-HG through screening FBS; Adding DEXAMETHASONE BP98 1 μ M, INDOMETHACIN BP99 200 μ M, IBMX 0.5mM, Regular Insulin 10 μ g/ml cultivated 3 days; Form promptly takes place and changes in cell, is shunk gradually by fusiform inoblast appearance to shorten, and 90% above cell becomes cube or polygon; Cultured continuously 7 days, there have small fat to ooze under the mirror in the visible cell to be existing, and along with the prolongation of incubation time, fat drips and increases gradually and merges, and when cultivating for 2 weeks, the agglomerating fat of visible fusion drips and is full of whole cell.The fat that produces in the oil red O stain visible cell is dyed redness by specificity.
(3) become chondrocyte induction
3 generations above cell, according to every pipe 2 * 10
5The cell branch installs to the 15ml polypropylene centrifuge tube; Low-speed centrifugal makes cell in test tube, form micelle; In containing the DMEM-HG of 2.5%FBS, add Regular Insulin, Transferrins,iron complexes, each 6.25 μ g/ml of Sodium Selenite, BSA 1.25 μ g/ml, Sodium.alpha.-ketopropionate 1mM/L; Xitix phosphoric acid 37.5 μ g/ml, TGF-β
150ng/ml is put in 37 ℃, 5%CO
2, cultivate under the saturated humidity, amount was changed liquid, 2 weeks of cultured continuously in per 3 days half.
After inducing for 2 weeks the cell micelle is broken up smear, the visible II Collagen Type VI of alcian blue (Alcian blue) dyeing forms extracellular matrix and is blue, and control group does not have indigo plant and dyes.
Through the detection of above a series of data targets, demonstrate and use the MSC that the inventive method separation obtains, have ability to scleroblast, adipocyte, chondrocyte's differentiation, confirm that the MSC that the inventive method obtains has the stem cell characteristic.
The foundation of embodiment 8, umbilical cord stem cell bank
1, the detection of cytoactive
Utilize the trypan blue staining to count the number of frozen front and back viable cell.
2, the detection of cell contamination
Utilize small amounts of cells to cultivate, detect cell and whether receive the pollution of fungi and bacterium.Utilize the etiology method, detect cell whether receive hepatitis B two double, third liver, AIDS, cytomegalovirus, Epstein-Barr virus and syphilis, HbsAg, HbsAb, HBcAb, HbeAg, HbeAb, HCVAb, HIV-1/2Ab, CMV-IgM and EBV-IgA, TRUST and infect.
3, the detection of inherited disease
Utilize the method for molecular genetics, detect freeze-stored cell and whether have inherited disease.
4, HLA-ABC/DR joins type
Detect cell HLA-ABC/DR phenotype, and place on record.
5, the investigation in cell source
Record fetus and father and mother's thereof detail file, and place on record.
6, the foundation of umbilical cord stem cell DB
After preserving normal umbilical cord stem cell, set up the DB of umbilical cord stem cell, comprising the first five items data, and foundation and freeze-stored cell is related.
Claims (10)
1. from the umbilical cord flesh tissue, separate and the method for amplification of mesenchymal stem cells, this method may further comprise the steps:
(1) sterilization and clean: with alcohol with the umbilical cord tissue surface sterilization; Umbilical cord is cut off from the centre, be tiled on the plate; Utilize the PBS cleansing tissue, to reduce structural red corpuscle;
(2) the adherent processing of umbilical cord tissue: tissue is cut into bulk, is tiled in another cell cultures plate again, the tissue block quantity in each plate maintains 5-20 piece (for example 10-15 piece); Made be attached on the plate in the air-dry 2-50 of tissue block minute until tissue;
(3) umbilical cord tissue is cultivated: slowly add the mescenchymal stem cell special culture media along the plate edge and get final product to organizing to flood; Put plate into CO
2Concentration is that 37 ℃ of incubators of 5% are cultivated, and is cultured to 3-7 days and plate is taken out from incubator when (for example 4-6 days, for example the 5th day), adds an amount of (tissue is flooded to get final product) mescenchymal stem cell special culture media; When 9-11 days (for example the 10th day), the substratum in the plate is shifted out, add an amount of (tissue is flooded to get final product) fresh mescenchymal stem cell special culture media, continue to cultivate; When 11-13 days (for example the 12nd day), remove all umbilical cord tissue pieces and continue and cultivate; After this (for example per 2 days) were once changed liquid entirely in every 1-3 days;
(4) passage: when the attached cell fusion rate in the plate reaches the 50-70% left and right sides, use digestive ferment (for example TrypLE Express, invitrogen product) to make attached cell break away from the plate bottom; Centrifugal, remove supernatant, add mescenchymal stem cell special culture media suspension cell again, be inoculated in the T25 Tissue Culture Flask and go down to posterity and carry out amplification cultivation; After this liquid was changed once in (for example per 2 days) in every 1-3 days, after fusion rate reaches 70-90%, promptly got umbilical cord mesenchymal stem cells, went down to posterity in case of necessity;
And optional following one or more steps:
(5) to step (4) gained umbilical cord mesenchymal stem cells, detect at least one item of following project: cytoactive, cell contamination, inherited disease, HLA-ABC/DR join type;
(6) umbilical cord mesenchymal stem cells after step (4) gained is gone down to posterity is frozen in liquid nitrogen, subsequent use.
2. according to the process of claim 1 wherein that said umbilical cord is the flesh tissue of umbilical cord.
3. according to the process of claim 1 wherein in the step (2), the tissue that shreds is the about 0.2-2.5 cubic centimetre of size.
4. according to the process of claim 1 wherein that in the step (2), the air-dry time of tissue block is 2-50 minute.
5. comprise FBS, L-Glutamine, Gentamicin and DMEM-F12 according to the process of claim 1 wherein in the said mescenchymal stem cell special culture media.
6. according to the process of claim 1 wherein:
The FBS that contains 10-20% in the said mescenchymal stem cell special culture media;
The L-Glutamine that contains 0.5-2% in the said mescenchymal stem cell special culture media;
The Gentamicin that contains 0.02-0.1% in the said mescenchymal stem cell special culture media; And/or
The DMEM-F12 that contains 80-90% in the said mescenchymal stem cell special culture media.
7. contain the Gentamicin of the L-Glutamine of the FBS of 15 weight parts of having an appointment, about 1 weight part, about 0.05 weight part and the DMEM-F12 of about 84 weight parts according to the process of claim 1 wherein in the said mescenchymal stem cell special culture media.
8. according to the method for claim 1, this method may further comprise the steps:
(1) sterilization and cleaning: in Biohazard Safety Equipment, with fresh umbilical cord tissue surface sterilization, umbilical cord is cut off from the centre, be tiled on the aseptic 10cm cell cultures plate, utilize the PBS cleansing tissue, to reduce to organize top red corpuscle as far as possible with alcohol;
(2) the adherent processing of umbilical cord tissue: tissue is transferred in another 10cm cell cultures plate, tissue is cut into big or small 1cm
3Square shape, be tiled in another 10cm cell cultures plate, the tissue block quantity in each plate maintains the 10-15 piece, makes be attached on the plate until tissue in the air-dry 10-15 of tissue block minute;
(3) umbilical cord tissue is cultivated: slowly add mescenchymal stem cell special culture media (15%FBS+1%L-Glutamine+0.05%Gentamicin+84%DMEM-F12) along the plate edge and get final product to organizing to flood; Plate is placed CO
2Concentration is that 37 ℃ of incubators of 5% are cultivated, and takes out plate from incubator when being cultured to the 5th day, adds 5ml mescenchymal stem cell special culture media; The tenth day the media transfer in the plate, add the fresh mescenchymal stem cell special culture media of 15ml; Remove all umbilical cord tissue pieces at the 12 day and continue to cultivate, once changed liquid in after this per two days entirely;
(4) passage: the attached cell fusion rate when the plate the inside reaches about 60%; Digestive ferment capable of using (TrypLE Express) breaks away from the plate bottom to attached cell; Remove supernatant after centrifugal; And add mescenchymal stem cell special culture media suspension cell again, be inoculated in the T25 Tissue Culture Flask and go down to posterity, and carry out amplification cultivation; After this changed liquid in per two days once after fusion rate reaches 80%, promptly get, go down to posterity again in case of necessity,
Randomly,
To above step (4) gained umbilical cord mesenchymal stem cells, detect at least one item of following project: cytoactive, cell contamination, inherited disease, HLA-ABC/DR join type; And/or
Umbilical cord mesenchymal stem cells after above step (4) gained gone down to posterity is frozen in liquid nitrogen, subsequent use.
9. set up the method for umbilical cord stem cell DB; It comprises the step of each said method of claim 1-8; And following steps: the cell after will going down to posterity is the frozen and relevant fetus information of record in liquid nitrogen, and carry out the biological characteristics and the evaluation of multidirectional differentiation potential of cell, and pair cell carries out the molecular genetics diagnosis; Preserve all related datas of cell, set up the DB of umbilical cord stem cell and carry out related with freeze-stored cell.
10. umbilical cord mesenchymal stem cells, it obtains according to each said method of claim 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101604052A CN102660503A (en) | 2012-05-22 | 2012-05-22 | Method for separating and amplifying mesenchymal stem cells from umbilical cord |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101604052A CN102660503A (en) | 2012-05-22 | 2012-05-22 | Method for separating and amplifying mesenchymal stem cells from umbilical cord |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102660503A true CN102660503A (en) | 2012-09-12 |
Family
ID=46770083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101604052A Pending CN102660503A (en) | 2012-05-22 | 2012-05-22 | Method for separating and amplifying mesenchymal stem cells from umbilical cord |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102660503A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105891512A (en) * | 2016-05-11 | 2016-08-24 | 天津普瑞赛尔生物科技有限公司 | Kit for identifying umbilical cord mesenchymal stem cells |
| CN106434557A (en) * | 2016-11-25 | 2017-02-22 | 博雅干细胞科技有限公司 | Method for preparing CD34 positive cells from umbilical cord mesenchymal stem cells |
| CN108486050A (en) * | 2018-03-31 | 2018-09-04 | 无锡博雅基因科技有限公司 | The method for preparing mescenchymal stem cell from the umbilical cord of dog |
| CN108795853A (en) * | 2018-05-28 | 2018-11-13 | 天津博雅秀岩生物技术有限公司 | Prepare the method and dog fetal membrane mescenchymal stem cell of dog fetal membrane mescenchymal stem cell |
| CN108865984A (en) * | 2018-06-22 | 2018-11-23 | 安徽 | A kind of preparation and extracting method of umbilical cord mesenchymal stem cells |
| CN110184236A (en) * | 2019-06-11 | 2019-08-30 | 华夏源（上海）细胞基因工程股份有限公司 | A kind of preparation method of amnion mesenchymal stem cell |
| CN111235100A (en) * | 2020-02-21 | 2020-06-05 | 新乡医学院 | Culture method of human umbilical cord blood mesenchymal stem cells |
| CN112195150A (en) * | 2020-10-22 | 2021-01-08 | 江苏拓弘康恒医药有限公司 | Method for improving primary acquisition of umbilical cord mesenchymal stem cells |
| CN112292447A (en) * | 2019-02-28 | 2021-01-29 | 京东方科技集团股份有限公司 | Umbilical cord mesenchymal stem cell and preparation method of cell membrane thereof |
| CN114921408A (en) * | 2022-05-25 | 2022-08-19 | 河北三臧生物科技有限公司 | Method for in-vitro large-scale culture and amplification of mesenchymal stem cells |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101831403A (en) * | 2010-05-21 | 2010-09-15 | 协和干细胞基因工程有限公司 | Method for amplifying mesenchymal stem cells of human umbilical cord and placenta in vitro |
| CN102010850A (en) * | 2009-12-15 | 2011-04-13 | 和泽生物科技有限公司 | Method for separating MSC (Mesenchymal Stem Cell) climbing sheets of umbilical tissue |
| CN102106342A (en) * | 2009-12-29 | 2011-06-29 | 山东省齐鲁干细胞工程有限公司 | Method for storing mesenchymal stem cells and method for culturing mesenchymal stem cells |
-
2012
- 2012-05-22 CN CN2012101604052A patent/CN102660503A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102010850A (en) * | 2009-12-15 | 2011-04-13 | 和泽生物科技有限公司 | Method for separating MSC (Mesenchymal Stem Cell) climbing sheets of umbilical tissue |
| CN102106342A (en) * | 2009-12-29 | 2011-06-29 | 山东省齐鲁干细胞工程有限公司 | Method for storing mesenchymal stem cells and method for culturing mesenchymal stem cells |
| CN101831403A (en) * | 2010-05-21 | 2010-09-15 | 协和干细胞基因工程有限公司 | Method for amplifying mesenchymal stem cells of human umbilical cord and placenta in vitro |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105891512A (en) * | 2016-05-11 | 2016-08-24 | 天津普瑞赛尔生物科技有限公司 | Kit for identifying umbilical cord mesenchymal stem cells |
| CN106434557A (en) * | 2016-11-25 | 2017-02-22 | 博雅干细胞科技有限公司 | Method for preparing CD34 positive cells from umbilical cord mesenchymal stem cells |
| CN106434557B (en) * | 2016-11-25 | 2019-08-13 | 博雅干细胞科技有限公司 | The method for preparing CD34 positive cell by umbilical cord mesenchymal stem cells |
| CN108486050A (en) * | 2018-03-31 | 2018-09-04 | 无锡博雅基因科技有限公司 | The method for preparing mescenchymal stem cell from the umbilical cord of dog |
| CN108486050B (en) * | 2018-03-31 | 2020-09-29 | 天津博雅秀岩生物技术有限公司 | Method for preparing mesenchymal stem cells from umbilical cord of dog |
| CN108795853A (en) * | 2018-05-28 | 2018-11-13 | 天津博雅秀岩生物技术有限公司 | Prepare the method and dog fetal membrane mescenchymal stem cell of dog fetal membrane mescenchymal stem cell |
| CN108795853B (en) * | 2018-05-28 | 2021-08-24 | 天津博雅秀岩生物技术有限公司 | Method for preparing canine fetal membrane mesenchymal stem cells and canine fetal membrane mesenchymal stem cells |
| CN108865984A (en) * | 2018-06-22 | 2018-11-23 | 安徽 | A kind of preparation and extracting method of umbilical cord mesenchymal stem cells |
| CN112292447A (en) * | 2019-02-28 | 2021-01-29 | 京东方科技集团股份有限公司 | Umbilical cord mesenchymal stem cell and preparation method of cell membrane thereof |
| CN112292447B (en) * | 2019-02-28 | 2023-03-31 | 京东方科技集团股份有限公司 | Umbilical cord mesenchymal stem cell and preparation method of cell membrane thereof |
| CN110184236A (en) * | 2019-06-11 | 2019-08-30 | 华夏源（上海）细胞基因工程股份有限公司 | A kind of preparation method of amnion mesenchymal stem cell |
| CN111235100B (en) * | 2020-02-21 | 2022-04-29 | 新乡医学院 | Culture method of human umbilical cord blood mesenchymal stem cells |
| CN111235100A (en) * | 2020-02-21 | 2020-06-05 | 新乡医学院 | Culture method of human umbilical cord blood mesenchymal stem cells |
| CN112195150A (en) * | 2020-10-22 | 2021-01-08 | 江苏拓弘康恒医药有限公司 | Method for improving primary acquisition of umbilical cord mesenchymal stem cells |
| CN114921408A (en) * | 2022-05-25 | 2022-08-19 | 河北三臧生物科技有限公司 | Method for in-vitro large-scale culture and amplification of mesenchymal stem cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102660497B (en) | Method for freezing and reviving umbilical cord tissues and for separating and increasing stem cells | |
| CN102807966B (en) | Method for freezing and thawing placental whole cells and separating and expanding stem cells | |
| CN102660502B (en) | Methods for freezing and thawing whole cell of umbilical cord and separating and augmenting stem cell | |
| CN102660501A (en) | Method for separating and amplifying mesenchymal stem cell from fresh tissue of umbilical cord | |
| CN102676451B (en) | Method for separating mesenchymal stem cells from placenta | |
| CN107236704B (en) | From the method for placenta separating mesenchymal stem cell and the digestive enzyme compositions used | |
| CN102660503A (en) | Method for separating and amplifying mesenchymal stem cells from umbilical cord | |
| CN102586184B (en) | Method for establishing placental mesenchyme stem cell library | |
| CN102106342B (en) | Method for storing mesenchymal stem cells and method for culturing mesenchymal stem cells | |
| CN102127522B (en) | Human umbilical mesenchymal stem cell and preparation method thereof | |
| CN109234229B (en) | Method for separating mesenchymal stem cells from placental blood vessels and digestive enzyme composition used in same | |
| CN107022521A (en) | Decidua vera tissue freezing, the method recovered and be separately cultured mescenchymal stem cell | |
| CN103396990A (en) | Method for preparing mesenchymal stem cells | |
| CN106465710A (en) | Fatty tissue frozen stock solution and fatty tissue cryopreservation methods | |
| CN104673745A (en) | Isolated culture method of porcine fat stem cells | |
| CN108456657A (en) | Dog umbilical cord mesenchymal stem cells and preparation method thereof and cryopreservation methods | |
| CN104450611A (en) | Primary separation and culture method of human amniotic mesenchymal stem cells | |
| CN101629165A (en) | Preparation method of umbilical cord Huatong glue mesenchymal stem cells and product thereof | |
| CN108486050A (en) | The method for preparing mescenchymal stem cell from the umbilical cord of dog | |
| CN102965335A (en) | Kit for mesenchymal stem cell culture and application thereof | |
| CN106434557A (en) | Method for preparing CD34 positive cells from umbilical cord mesenchymal stem cells | |
| CN102154200B (en) | Preparation and storage of mesenchymal stem cells for clinical treatment | |
| CN104694464A (en) | Clinical dental pulp stem cell and preparation method thereof | |
| CN105219707A (en) | A kind of method of recovery fat mesenchymal stem cell | |
| CN103380769A (en) | Long-time preservation solution of adipose tissue for isolated culture of stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120912 |